Trulieve publishes investor presentation highlighting US medical cannabis scale, NYSE listing shift to DEA-registered operations
TRLV•Investor presentation highlights scale, restructuring and 2025 results
Trulieve highlighted its NYSE listing under ticker TRLV, following federal rescheduling of medical marijuana to Schedule III in April 2026.
Corporate restructuring deconsolidated mixed medical and adult-use operations into “Harvest”; Trulieve retains a 90% economic interest.
Core consolidated footprint:
- 206 DEA-registered medical dispensaries
- 3.5 million square feet of cultivation and processing capacity across Florida, Georgia, Pennsylvania, and West Virginia
2025 results included:
- $1.2 billion revenue
- 60% gross margin
- $273 million cash flow from operations
Key growth drivers cited were Georgia program expansion with pharmacy distribution from July 1, 2026, and a Texas buildout pending final license approval expected in 2026.
